FHACT® takes the guess work out of cervical cancer screening

WATCH THE VIDEO >

Get answers,
get FHACT®.
Webinar series.

LEARN MORE >

FHACT® is indicated for HPV-positive ASCUS and LSIL patients.

LEARN MORE >

FHACT® is the only FISH Probe to assess four biomarkers associated with cervical cancer.

Learn More

Latest News

05 Feb 16

Cancer Genetics, Inc. Expands the Reach of Precision Medicine by Over 2.6 Million Individuals as it Signs a New Agreement With Blue Cross Blue Shield of Minnesota (read more...)

- RUTHERFORD, N.J. & LOS ANGELES, Feb. 05, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"), a leader in (read more...)
21 Jan 16

Cancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use in Clinical Trials, Translational Research, and Therapy Selection for Patients (read more...)

- Immuno-oncology drugs are expected to reach $35 billion in sales by 2024 and potentially impact up to 60% of all cancer patients Cancer Genetics, (read more...)

Events

02 Dec 15

Piper Jaffray 27th Annual Healthcare Conference

02 Dec 15

Piper Jaffray 27th Annual Healthcare Conference | Fireside Chat

10 Nov 15

3rd Quarter 2015 Conference Call

- Dial-In InformationDomestic: 877-407-4018International: 201-689-8471Conference ID: 13622111 <!--Replay InformationDomestic: 877-870-(read more...)
Clinicians
Patients